Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.
- DOI
- 10.1007/s13300-026-01907-y
- Published
- 2026 Sep 17
- Container
- Diabetes therapy : research, treatment and education of diabetes and related disorders
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13300-026-01907-y,
title = {Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.},
author = {Stewart KD and Matza LS and Chinthammit C and Pavo I and Bartee AK and Boye KS},
year = {2026},
journal = {Diabetes therapy : research, treatment and education of diabetes and related disorders},
doi = {10.1007/s13300-026-01907-y},
url = {https://doi.org/10.1007/s13300-026-01907-y}
}RIS
TY - JOUR TI - Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial. AU - Stewart KD AU - Matza LS AU - Chinthammit C AU - Pavo I AU - Bartee AK AU - Boye KS PY - 2026 JO - Diabetes therapy : research, treatment and education of diabetes and related disorders DO - 10.1007/s13300-026-01907-y UR - https://doi.org/10.1007/s13300-026-01907-y ER -
APA
KD, S., LS, M., C, C., I, P., AK, B., & KS, B. (2026). Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.. Diabetes therapy : research, treatment and education of diabetes and related disorders. https://doi.org/10.1007/s13300-026-01907-y
Source records
- pubmed · retrieved 2026-09-25T18:20:51.392Z